Buchumschlag

Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine

This post hoc subgroup analysis of a large phase 3 study compared the efficacy and safety of eribulin versus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who received second-line treatment. In the phase 3 study, women with advanced/m...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Pivot, Xavier (VerfasserIn) , Marmé, Frederik (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 4 January 2018
In: Breast cancer
Year: 2018, Jahrgang: 25, Heft: 3, Pages: 370-374
ISSN:1880-4233
DOI:10.1007/s12282-017-0826-4
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s12282-017-0826-4
Verlag, lizenzpflichtig, Volltext: https://link.springer.com/article/10.1007/s12282-017-0826-4
Volltext
Verfasserangaben:Xavier Pivot, Seock Ah Im, Matthew Guo, Frederik Marmé

MARC

LEADER 00000caa a2200000 c 4500
001 1695791746
003 DE-627
005 20220818051940.0
007 cr uuu---uuuuu
008 200423s2018 xx |||||o 00| ||eng c
024 7 |a 10.1007/s12282-017-0826-4  |2 doi 
035 |a (DE-627)1695791746 
035 |a (DE-599)KXP1695791746 
035 |a (OCoLC)1341316451 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Pivot, Xavier  |e VerfasserIn  |0 (DE-588)1155130502  |0 (DE-627)1016504047  |0 (DE-576)501443800  |4 aut 
245 1 0 |a Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine  |c Xavier Pivot, Seock Ah Im, Matthew Guo, Frederik Marmé 
264 1 |c 4 January 2018 
300 |a 5 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 23.04.2020 
520 |a This post hoc subgroup analysis of a large phase 3 study compared the efficacy and safety of eribulin versus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who received second-line treatment. In the phase 3 study, women with advanced/metastatic breast cancer and ≤ 3 prior chemotherapies were randomized 1:1 to eribulin mesilate 1.4 mg/m2 intravenously on days 1 and 8, or twice-daily oral capecitabine 1.25 g/m2 on days 1-14 (21-day cycles). This analysis included 392 patients. Median overall survival was longer in patients receiving eribulin compared with capecitabine (16.1 vs 13.5 months, respectively; HR 0.77, P = 0.026). Median progression-free survival and response rates were similar between arms. Both treatments had manageable safety profiles. 
700 1 |a Marmé, Frederik  |d 1974-  |e VerfasserIn  |0 (DE-588)132561972  |0 (DE-627)52394893X  |0 (DE-576)299226549  |4 aut 
773 0 8 |i Enthalten in  |t Breast cancer  |d Berlin : Springer, 1994  |g 25(2018), 3, Seite 370-374  |h Online-Ressource  |w (DE-627)548636184  |w (DE-600)2394259-9  |w (DE-576)281357080  |x 1880-4233  |7 nnas  |a Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine 
773 1 8 |g volume:25  |g year:2018  |g number:3  |g pages:370-374  |g extent:5  |a Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine 
856 4 0 |u https://doi.org/10.1007/s12282-017-0826-4  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://link.springer.com/article/10.1007/s12282-017-0826-4  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200423 
993 |a Article 
994 |a 2018 
998 |g 132561972  |a Marmé, Frederik  |m 132561972:Marmé, Frederik  |d 910000  |d 910400  |e 910000PM132561972  |e 910400PM132561972  |k 0/910000/  |k 1/910000/910400/  |p 4  |y j 
999 |a KXP-PPN1695791746  |e 3631224052 
BIB |a Y 
SER |a journal 
JSO |a {"id":{"eki":["1695791746"],"doi":["10.1007/s12282-017-0826-4"]},"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabineBreast cancer","note":["Gesehen am 08.11.13"],"origin":[{"publisherPlace":"Berlin ; Tokyo","dateIssuedDisp":"1994-","publisher":"Springer ; Japanese Breast Cancer Soc.","dateIssuedKey":"1994"}],"pubHistory":["1.1994 -"],"title":[{"title":"Breast cancer","title_sort":"Breast cancer","subtitle":"the journal of the Japanese Breast Cancer Society"}],"id":{"eki":["548636184"],"issn":["1880-4233"],"zdb":["2394259-9"]},"recId":"548636184","physDesc":[{"extent":"Online-Ressource"}],"part":{"volume":"25","extent":"5","pages":"370-374","year":"2018","text":"25(2018), 3, Seite 370-374","issue":"3"},"language":["eng"]}],"recId":"1695791746","physDesc":[{"extent":"5 S."}],"name":{"displayForm":["Xavier Pivot, Seock Ah Im, Matthew Guo, Frederik Marmé"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine","title_sort":"Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine"}],"note":["Gesehen am 23.04.2020"],"origin":[{"dateIssuedDisp":"4 January 2018","dateIssuedKey":"2018"}],"language":["eng"],"person":[{"family":"Pivot","display":"Pivot, Xavier","role":"aut","given":"Xavier"},{"given":"Frederik","role":"aut","display":"Marmé, Frederik","family":"Marmé"}]} 
SRT |a PIVOTXAVIESUBGROUPAN4201 

Ähnliche Einträge